Plasma hyaluronic acid level as a prognostic and monitoring marker of metastatic breast cancer

International Journal of Cancer

Volumn 138, Issue 10, 2016, Pages 2499-2509

  Peng, Cike ^a,b   Wallwiener, Markus ^b   Rudolph, Anja ^a   Cük, Katarina ^a,b   Eilber, Ursula ^a   Celik, Muhabbet ^a   Modugno, Caroline ^b   Trumpp, Andreas ^a,c   Heil, Jörg ^b   Marmé, Frederik ^b   Madhavan, Dharanija ^a,b   Nees, Juliane ^b   Riethdorf, Sabine ^d   Schott, Sarah ^b   Sohn, Christof ^b   Pantel, Klaus ^d   Schneeweiss, Andreas ^b   Chang Claude, Jenny ^a   Yang, Rongxi ^a,b,e   Burwinkel, Barbara ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Exp Hematology Group Heidelberg Institute for Stem Cell Technology and Experimental Medicine GGmbH   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

biomarker; hyaluronic acid; metastatic breast cancer; plasma; prognosis

Indexed keywords

HYALURONIC ACID; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER REGRESSION; CIRCULATING TUMOR CELL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; BLOOD; BREAST NEOPLASMS; CASE CONTROL STUDY; COHORT ANALYSIS; KAPLAN MEIER METHOD; METASTASIS; MORTALITY; OUTCOME ASSESSMENT; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; HYALURONIC ACID; KAPLAN-MEIER ESTIMATE; NEOPLASM METASTASIS; PATIENT OUTCOME ASSESSMENT; PROGNOSIS; ROC CURVE;

EID: 84959871794     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29975     Document Type: Article

References (40)

1. Giordano A, Cristofanilli M., CTCs in metastatic breast cancer. Recent Results Cancer Res 2012; 195: 193-201.
2. Beslija S, Bonneterre J, Burstein H, et al., Second consensus on medical treatment of metastatic breast cancer. Ann Oncol 2007; 18: 215-25.
3. Baccelli I, Schneeweiss A, Riethdorf S, et al., Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 2013; 31: 539-44.
4. Parkinson DR, Dracopoli N, Petty BG, et al., Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med 2012; 10: 138
5. Wallwiener M, Hartkopf AD, Baccelli I, et al., The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Breast Cancer Res Treat 2013; 137: 503-10.
6. Riethdorf S, Wikman H, Pantel K., Review: biological relevance of disseminated tumor cells in cancer patients. Int J Cancer 2008; 123: 1991-2006.
7. Lianidou ES, Markou A., Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges. Clin Chem 2011; 57: 1242-55.
8. Mostert B, Kraan J, Bolt-de Vries J, et al., Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146. Breast Cancer Res Treat 2011; 127: 33-41.
9. Pantel K, Alix-Panabieres C., Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med 2010; 16: 398-406.
10. Mani SA, Guo W, Liao MJ, et al., The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-15.
11. Bonnomet A, Brysse A, Tachsidis A, et al., Epithelial-to-mesenchymal transitions and circulating tumor cells. J Mammary Gland Biol Neoplasia 2010; 15: 261-73.
12. Gertler R, Rosenberg R, Fuehrer K, et al., Detection of circulating tumor cells in blood using an optimized density gradient centrifugation. Recent Results Cancer Res 2003; 162: 149-55.
13. Balic M, Dandachi N, Hofmann G, et al., Comparison of two methods for enumerating circulating tumor cells in carcinoma patients. Cytometry B Clin Cytom 2005; 68: 25-30.
14. Ring AE, Zabaglo L, Ormerod MG, et al., Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques. Br J Cancer 2005; 92: 906-12.
15. Tammi RH, Kultti A, Kosma VM, et al., Hyaluronan in human tumors: pathobiological and prognostic messages from cell-associated and stromal hyaluronan. Semin Cancer Biol 2008; 18: 288-95.
16. Toole BP., Hyaluronan in morphogenesis. J Intern Med 1997; 242: 35-40.
17. Hajime M, Shuichi Y, Makoto N, et al., Inhibitory effect of 4-methylesculetin on hyaluronan synthesis slows the development of human pancreatic cancer in vitro and in nude mice. Int J Cancer 2007; 120: 2704-9.
18. de la Motte CA, Hascall VC, Drazba J, et al., Mononuclear leukocytes bind to specific hyaluronan structures on colon mucosal smooth muscle cells treated with polyinosinic acid:polycytidylic acid: inter-alpha-trypsin inhibitor is crucial to structure and function. Am J Pathol 2003; 163: 121-33.
19. Yabushita H, Kishida T, Fusano K, et al., Role of hyaluronan and hyaluronan synthase in endometrial cancer. Oncol Rep 2005; 13: 1101-5.
20. Aghcheli K, Parsian H, Qujeq D, et al., Serum hyaluronic acid and laminin as potential tumor markers for upper gastrointestinal cancers. Eur J Intern Med 2012; 23: 58-64.
21. Delpech B, Chevallier B, Reinhardt N, et al., Serum hyaluronan (hyaluronic acid) in breast cancer patients. Int J Cancer 1990; 46: 388-90.
22. Vrieling A, Buck K, Heinz J, et al., Pre-diagnostic alcohol consumption and postmenopausal breast cancer survival: a prospective patient cohort study. Breast Cancer Res Treat 2012; 136: 195-207.
23. Lindqvist U, Engstrom-Laurent A, Laurent U, et al., The diurnal variation of serum hyaluronan in health and disease. Scand J Clin Lab Invest 1988; 48: 765-70.
24. Riethdorf S, Fritsche H, Muller V, et al., Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res 2007; 13: 920-8.
25. Haserodt S, Aytekin M, Dweik RA., A comparison of the sensitivity, specificity, and molecular weight accuracy of three different commercially available Hyaluronan ELISA-like assays. Glycobiology 2011; 21: 175-83.
26. Cristofanilli M, Budd GT, Ellis MJ, et al., Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-91.
27. Millner LM, Linder MW, Valdes R. Jr,. Circulating tumor cells: a review of present methods and the need to identify heterogeneous phenotypes. Ann Clin Lab Sci 2013; 43: 295-304.
28. Colzani E, Liljegren A, Johansson AL, et al., Prognosis of patients with breast cancer: causes of death and effects of time since diagnosis, age, and tumor characteristics. J Clin Oncol 2011; 29: 4014-21.
29. Toole BP., Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 2004; 4: 528-39.
30. Zhang L, Underhill CB, Chen L., Hyaluronan on the surface of tumor cells is correlated with metastatic behavior. Cancer Res 1995; 55: 428-33.
31. El-Mezayen HA, Toson el SA, Darwish H, et al., Development of a novel metastatic breast cancer score based on hyaluronic acid metabolism. Med Oncol 2013; 30: 404
32. Stern R, Asari AA, Sugahara KN., Hyaluronan fragments: an information-rich system. Eur J Cell Biol 2006; 85: 699-715.
33. Sugahara KN, Hirata T, Hayasaka H, et al., Tumor cells enhance their own CD44 cleavage and motility by generating hyaluronan fragments. J Biol Chem 2006; 281: 5861-8.
34. Auvinen P, Rilla K, Tumelius R, et al., Hyaluronan synthases (HAS1-3) in stromal and malignant cells correlate with breast cancer grade and predict patient survival. Breast Cancer Res Treat 2014; 143: 277-86.
35. Karihtala P, Soini Y, Auvinen P, et al., Hyaluronan in breast cancer: correlations with nitric oxide synthases and tyrosine nitrosylation. J Histochem Cytochem 2007; 55: 1191-8.
36. Chen J, Li N, Li G., Link protein hyaluronan-binding motif abrogates CD44-hyaluronan-mediated leukemia-liver cell adhesion. Mol Clin Oncol 2013; 1: 483-6.
37. Ouhtit A, Abd Elmageed ZY, Abdraboh ME, et al., In vivo evidence for the role of CD44s in promoting breast cancer metastasis to the liver. Am J Pathol 2007; 171: 2033-9.
38. Casalini P, Carcangiu ML, Tammi R, et al., Two distinct local relapse subtypes in invasive breast cancer: effect on their prognostic impact. Clin Cancer Res 2008; 14: 25-31.
39. Yahya RS, El-Bindary AA, El-Mezayen HA, et al., Biochemical evaluation of hyaluronic acid in breast cancer. Clin Lab 2014; 60: 1115-21.
40. Weiss I, Trope CG, Reich R, et al., Hyaluronan synthase and hyaluronidase expression in serous ovarian carcinoma is related to anatomic site and chemotherapy exposure. Int J Mol Sci 2012; 13: 12925-38.